Participating Institutions
The global partnership of academic and medical research organisations collaborating to map how the human body builds protective immunity to Streptococcus pyogenes.
Amsterdam, Netherlands
Glycan array screening to test how human IgG and IgA antibodies recognise synthetic structures and variants on the Strep A cell wall.
London, United Kingdom
London school cohorts (including the TraCK study) tracking children through scarlet fever seasons, functional antibody killing and toxin neutralisation assays, pooled adult studies, and immune gene sequencing.
Banjul, The Gambia
Longitudinal household (SpyCATS) and school cohorts in The Gambia collecting oral fluid and blood samples before, during, and after Strep A skin and throat infections.
Lund, Sweden
Quantitative and structural mass spectrometry to identify which Strep A proteins and binding sites are recognised by protective human antibodies.
Perth, Australia
Studying how Strep A colonises and invades human tonsil cells, how antibodies block throat attachment, and how children respond to sore throat infections in Perth cohorts.
Bristol, United Kingdom
Human tonsil organoid models comparing how mucosal B cells and T cells from young children and adults respond to Strep A proteins.
Cape Town, South Africa
Affinity purification of protective anti-streptococcal antibodies from South African adult alongside prospective clinical cohorts in Cape Town.
Oxford, United Kingdom
Single-cell profiling of conventional and unconventional T cells, including mucosal cells and commensal-reactive T cells.
London, Canada
Humanised -transgenic mouse models investigating how Strep A superantigens delay immunity and how protection develops after repeated infections.
Durham, United States
Systems serology and multiplex assays measuring antibody binding strength, IgG and IgA subclasses, and Fc-receptor effector functions.
Belo Horizonte, Brazil
Well-characterised patient and control cohorts in Brazil, profiling cytokines and T-cell responses linked to heart valve autoimmunity.
Suva, Fiji
Clinical epidemiology and serosurveillance cohorts in Fijian children across high-burden settings of strep throat, impetigo, and rheumatic heart disease.
La Jolla, United States
Genome-wide B-cell and T-cell epitope mapping using the alongside germinal center cell studies using assays.
Melbourne, Australia
World-first Controlled Human Infection Model () of Strep A pharyngitis in adult volunteers across M75 and M1 challenge and rechallenge trials.
Perth, Australia
Translational Strep A and acute rheumatic fever prevention research connecting clinical surveillance across Australia and the Pacific.
La Jolla, United States
Neutrophil antibody killing () and virulence-blocking assays, human T-cell and B-cell immunity, and -conjugate (VAX-A1) and SpeA toxoid vaccine studies.
Auckland, New Zealand
New Zealand childhood pharyngitis, impetigo, and cohorts paired with pan-proteome phage display for Strep A and cardiac autoantibodies.
Brisbane, Australia
Preclinical development and head-to-head adjuvant testing of the multi-protein Combo#5 subunit and mRNA Strep A vaccines.